As of January 22, 2025, Lexicon Pharmaceuticals (LXRX) has a market cap of $0.30 billion USD. According to our data, Lexicon Pharmaceuticals is ranked No.6674 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.30 B |
13.51%
|
Dec 31, 2024 | $0.27 B |
-51.63%
|
Dec 29, 2023 | $0.55 B |
-19.90%
|
Dec 30, 2022 | $0.69 B |
-51.52%
|
Dec 31, 2021 | $1.42 B |
15.20%
|
Dec 31, 2020 | $1.24 B |
-17.59%
|
Dec 31, 2019 | $1.50 B |
-37.50%
|
Dec 31, 2018 | $2.40 B |
-32.79%
|
Dec 29, 2017 | $3.57 B |
-28.56%
|
Dec 30, 2016 | $5.00 B |
3.91%
|
Dec 31, 2015 | $4.81 B |
108.95%
|
Dec 31, 2014 | $2.30 B |
-49.44%
|
Dec 31, 2013 | $4.55 B |
-18.55%
|
Dec 31, 2012 | $5.59 B |
71.32%
|
Dec 30, 2011 | $3.26 B |
-10.42%
|
Dec 31, 2010 | $3.64 B |
-15.29%
|
Dec 31, 2009 | $4.30 B |
21.43%
|
Dec 31, 2008 | $3.54 B |
-53.80%
|
Dec 31, 2007 | $7.67 B |
-16.07%
|
Dec 29, 2006 | $9.13 B |
-1.10%
|
Dec 30, 2005 | $9.24 B |
-52.96%
|
Dec 31, 2004 | $19.64 B |
31.75%
|
Dec 31, 2003 | $14.90 B |
24.52%
|
Dec 31, 2002 | $11.97 B |
-59.01%
|
Dec 31, 2001 | $29.20 B |
-30.59%
|
Dec 29, 2000 | $42.07 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Novo Nordisk
NVO
|
$335.24 B |
64.098 B
|
Denmark
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
GlaxoSmithKline
GSK
|
$68.21 B |
-0.002 M
|
UK
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
Market Cap | = | LXRX Stock Price | * | LXRX Shares Outstanding |
= | $0.84 | * | 0.36 B | |
= | $0.30 B |